Anacor Pharmaceuticals Inc

Most Recent

  • uploads///Part  Graph
    Company & Industry Overviews

    How Did Ziopharm Keep XBI from Losing More Ground?

    Year-to-date, Ziopharm has a return of -12.5%. Ziopharm has a book value of $0.72. With its current price, the stock is trading at a PBV ratio of 10.1x.

    By Peter Neil
  • uploads///Dupixent
    Company & Industry Overviews

    Dupixent Could Substantially Drive Regeneron’s Growth

    In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    New Product Launches May Boost Valeant’s Dermatology Revenue

    New product launches Despite upcoming patent expirations for drugs Elidel, Solodyn, and Acanya in 2018, and Zyclara in 2019, Valeant Pharmaceuticals (VRX) expects to boost its dermatology revenue after 2018 through new product launches. On December 12, 2016, the company hired Bill Humpries as executive vice president and head of the dermatology team. The change […]

    By Margaret Patrick
  • uploads///ANAC PFE downside
    Miscellaneous

    Pfizer Purchases Anacor in a $5.2 Billion Cash Deal

    On May 16, 2016, Pfizer (PFE) announced that it was acquiring dermatology pharma company Anacor (ANAC) in a transaction valued at $5.2 billion.

    By Brent Nyitray, CFA, MBA
  • uploads///Part  Graph
    Company & Industry Overviews

    Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva

    Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages

    By Peter Neil
  • uploads///Jublia
    Company & Industry Overviews

    Behind Valeant’s Significant Drop in Jublia Sales

    In 4Q15, Jublia added $68 million to the top line of Valeant—the sixth-largest revenue contributor in 4Q15, down from the second-largest in 3Q15.

    By Jillian Dabney
  • uploads///Guidance for
    Earnings Report

    Expectations for Valeant Pharmaceuticals in 2016

    Valeant Pharmaceuticals (VRX) expects 2016 revenues to be $12.5–12.7 billion, up by 21%. In January 2016, the company launched its Valeant Access Program in partnership with Walgreens.

    By Jillian Dabney
  • uploads///Jublia revenue
    Earnings Report

    Jublia: Valeant’s Major Drug in Its Dermatology Portfolio

    Revenue from Jublia amounted to $106 million, or 3.8%, of Valeant Pharmaceuticals’ (VRX) total revenue for 3Q15. At peak sales, Valeant expects Jublia to generate $300–$800 million.

    By Jillian Dabney
  • uploads///Part
    Company & Industry Overviews

    Anacor Pharmaceuticals Outperforms the Market

    Within IBB, stocks like Receptos and Celgene performed well. However, Anacor Pharmaceuticals outperformed everyone with an eye-catching 71.92% for the week ending July 17.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Healthcare and Biotech Stocks Accelerate Their Longer-Term Trends

    As of July 17, 2015, 68.42% of the biotech sector within the iShares Nasdaq Biotechnology (IBB) stocks are trading above their 100-day moving average.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Mergers and Acquisitions Drive the Biotech Sector

    Mergers and acquisitions continue to drive the biotech sector. In the week ending July 17, 2015, Celgene (CELG) acquired Receptos (RCPT) for ~$7.2 billion.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.